Publication: 2176

Bevacizumab and risk of arterial and venous thromboembolism in metastatic castration-resistant prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)
      QxMD      Google Scholar   
Citation:
Cancer vol 121 (7) 1025-1031
Year:
2015
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
4
Parents:
2145  
Children:
None
Program:
OGC
Primary Committee:
GU
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, CA33601, U01 GM063340, CA47577, U01 GM061393, P30 CA006973, U10 CA180802, CA41287, U10 CA021115, U10 CA031946, U01GM61393, CA77651, U10 CA033601, CA180820, CA180802, CA60138, U10 CA180821, R01 CA161608, R25 CA174664, P30 CA008748, P30 CA076292, GM61390, U01 GM061390, U10 CA016116, U10 CA180882, U19 GM061390, U10 CA180820, U01 HG007437, U10 CA180838, CA21115, CA31946, CA16116  
Corr. Author:
 
Authors:
                               
Networks:
CA824, LAPS-IL036, LAPS-IL057, LAPS-MD017, LAPS-MN026, LAPS-NC007, LAPS-NY016, NC002   
Study
CALGB-90401
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
arterial, venous, thromboembolism, bevacizumab, prostate, cancer, risk